Advances in metastatic prostate cancer circulating tumor cell enrichment technologies and clinical studies [0.03%]
前列腺癌循环肿瘤细胞捕获与富集技术的临床应用进展
Naira Essam Abou-Ghali,Paraskevi Giannakakou
Naira Essam Abou-Ghali
Circulating tumor cells (CTCs) have emerged as a pivotal tool that enables molecular interrogation of patient tumor cells and association with clinical outcomes. In prostate cancer specifically, where tumor biopsies from patients with bone ...
Youbin Zhang,David Scholten,Wenan Qiang et al.
Youbin Zhang et al.
During cancer metastasis, tumor cells migrate from the primary tumor site and spread to distant tissue or organs through the circulatory system of the body. While it is challenging to track metastatic tumor cells, circulating tumor cells (C...
Areeb Lutfi,Maaz Khan Afghan,Pashtoon Murtaza Kasi
Areeb Lutfi
Liquid biopsy, which includes both circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) has become a valuable tool for cancer diagnosis and monitoring. It offers a less invasive approach than traditional tissue biopsy and recent...
Circulating tumor cells in lung cancer: Integrating stemness and heterogeneity to improve clinical utility [0.03%]
肺癌循环肿瘤细胞的研究进展：整合干细胞特性及异质性以提高临床应用价值
Teresa Beninato,Giuseppe Lo Russo,Rita Leporati et al.
Teresa Beninato et al.
Circulating tumor cells (CTC), released by primary tumors into the bloodstream, represent a valuable source to inform on cancer heterogeneity, cancer progression, metastatic disease and therapy efficacy without the need of invasive tumor bi...
Circulating biomarkers for diagnosis, prognosis, and treatment response prediction in cancer [0.03%]
癌症诊断、预后及治疗反应预测的循环生物标志物
Lorenzo Galluzzi,Sheila Spada
Lorenzo Galluzzi
Identification of circulating tumor DNA as a biomarker for diagnosis and response to therapies in cancer patients [0.03%]
循环肿瘤DNA作为癌症患者诊断和治疗反应生物标志物的鉴定
Ronan W Hsieh,Lynn K Symonds,Jason Siu et al.
Ronan W Hsieh et al.
The sampling of circulating biomarkers provides an opportunity for non-invasive evaluation and monitoring of cancer activity. In modern day practice, this has typically been in the form of circulating tumor DNA (ctDNA) detected in plasma. T...
Nectin-4: A promising prognostic marker and therapeutic target in cancer [0.03%]
nectin-4：癌症预后的新标志物和治疗靶点
Shilpa Kuttikrishnan,Kirti S Prabhu,Ummu Habeeba et al.
Shilpa Kuttikrishnan et al.
Nectin cell adhesion protein 4 (Nectin-4), a calcium-independent immunoglobulin-like protein, has garnered significant attention in oncology due to its pronounced overexpression in malignant tumors and absence in healthy adult tissues. Elev...
Interleukin 10: Bridging the chasms in the immune landscape of multiple myeloma [0.03%]
interleukin 10：弥合多发性骨髓瘤免疫景观的鸿沟
Queenie Fernandes,Abdul W Ansari,Karama Makni-Maalej et al.
Queenie Fernandes et al.
Multiple myeloma (MM) is a complex hematologic malignancy characterized by the abnormal proliferation of plasma cells in the bone marrow, leading to significant clinical challenges and a high burden of morbidity and mortality. Interleukin 1...
Expanding frontiers in liquid biopsy-discovery and validation of circulating biomarkers in renal cell carcinoma and bladder cancer [0.03%]
液体活检领域的拓展-肾细胞癌和膀胱癌循环生物标志物的鉴定与验证
Sabareeswaran Krishnan,Shruthi Kanthaje,Punchappady Devasya Rekha et al.
Sabareeswaran Krishnan et al.
Renal cell carcinoma (RCC) and Bladder cancer (BC) are two lethal urological cancers that require diagnosis at their earliest stage causing decreasing survival rates in case of aggressive disease. However, there is no reliable circulating m...
Circulating biomarkers for diagnosis and response to therapies in cancer patients [0.03%]
癌症患者的循环生物标志物用于诊断和评估治疗反应
Natália Marcéli Stefanes,Maria Eduarda Cunha-Silva,Lisandra de Oliveira Silva et al.
Natália Marcéli Stefanes et al.
Cancer presents a significant challenge to global health, driving worldwide concerted efforts to advance early detection, predict therapeutic response, and identify novel targeted therapies. Liquid biopsies emerge as promising avenues for d...